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Fig. 1. Clinical entities in which inotropes are used. A
overlaps with advanced heart failure (AdvHF), as the
suffer from acute decompensation of the chronic form
shock (CS) represents a subset of AHF patients.
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Inotropes aim at increasing cardiac output by enhancing cardiac
contractility. They constitute the third pharmacological pillar in the
treatment of patients with decompensated heart failure (HF), the
other two being diuretics and vasodilators [1]. Decompensated HF
patients who need inotropic support belong to two distinct, though
partly overlapping, subpopulations, namely acutely decompensated or
acute HF (AHF) and advanced HF (AdvHF, Fig. 1). Acute HF is
characterized by a rapidly or gradually evolving hemodynamic
derangement, characterized usually by congestion and less commonly
by low cardiac output [1]. Advanced HF, on the other hand, represents
a severe, sometimes end-stage, form of the syndrome, characterized
usually by low cardiac output, with or without congestion [2]. In either
conditions, treatment with inotropes may be needed to manage low
cardiac output that results in end-organ hypoperfusion,with orwithout
hypotension, despite adequate or even elevated ﬁlling pressures.
Besides symptomatic improvement, however, there is no compelling
evidence suggesting a survival beneﬁt of inotropes by a series of clinical
studies [3,4]. In contrast, some inotropes have even been associated
with increased short and long-term mortality in clinical trials [5,6] and
propensity score-matched analyses of registries [7,8]. The negative
effect on survival has been attributed to a series of inherited detrimental
effects of inotropes, including myocardial ischemia, hypotension,
tachycardia, and arrhythmogenesis [9]. On the other hand, adverse
inotrope outcomes may also be related to the fact that their use is
sometimes inappropriate. Registry data show that inotropes are often
administered in patients with normal or even increased systolic blood
pressure, including 14% of patients with systolic blood pressure (SBP)
higher than 120 mmHg (OPTIMIZE registry), 13% of those with SBP
N160 mmHg (ALARM-HF registry) and 4% of those with SBP N180
mmHg (European Heart Failure Survey II), as well as in 8%–10% of
patients with HF with preserved ejection fraction (ADHERE registry)cute heart failure (AHF) often
vast majority of patients AHF
of the syndrome. Cardiogenic[10–13]. Therefore, there is a clear need to improve both the
identiﬁcation of patients who really need inotropic support, and the
selection of the proper inotrope in each case [14].
The present consensus document sought to address the issue of
inotrope use in the setting of both AHF and AdvHF. The paper
summarizes the key messages derived by an expert panel meeting,
organized by the Heart Failure Unit of the Second Department of
Cardiology, Attikon University Hospital, National and Kapodistrian
University of Athens, Greece, held in Athens in September 2018 and
attended by experts from 21 countries (Austria, Belgium, Croatia,
Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany,
Greece, Hungary, Israel, Italy, Poland, Russia, Slovenia, Spain, Sweden,
Switzerland, and Turkey).2. Current inotropes
Based on the main mechanism of action, there are three classes of
parenterally administered inotropes currently indicated for the
treatment of decompensated HF, (i) the beta adrenergic agonists,
including primarily dopamine and dobutamine and also the
catecholamines epinephrine and norepinephrine, (ii) the
phosphodiesterase III inhibitor (PDEi) milrinone and enoximone and
(iii) the calcium sensitizer levosimendan (Table 1) [14].2.1. Beta agonists
β-agonists stimulate the sarcolemmal beta-1 adrenergic receptor of
cardiomyocytes, leading to increased activation of intracellular adenyl
cyclase, increased synthesis of cyclic adenosine monophosphate
(cAMP), increased release of Ca2+ from sarcoplasmic reticulum and
thus enhanced actin-myosin interaction and ultimately increased
contractility, by means that also increase myocardial oxygen demand
[15]. The different beta agonists bear diverse pharmacologic properties
because of their diverse afﬁnity for the beta-1 receptors and their action
on other receptors.
Dopamine is an endogenous molecule. At low doses (0.5 to 2.5
μg/kg/min), it causes renal and splanchnic vasodilation and increase in
renal blood ﬂow, independently of cardiac output, through the
activation of dopaminergic receptors 1 and 2. At moderate doses (3 to
5 μg/kg/min), it exerts mainly inotropic and chronotropic effects
through beta-1 receptors, while at higher doses (N5 μg/kg/min), it
causes vasoconstriction by stimulating alpha-1 adrenergic receptors
[16].
Dobutamine is a synthetic analogue of dopamine with mainly
inotropic and less chronotropic properties. At lowdoses (b5 μg/kg/min),
it induces inotropic and mild vasodilatory effects that may cause
hypotension, while at higher doses (N10 μg/kg/min), it exerts inotropic,
chronotropic, and mild vasoconstrictive actions.
Table 1
Inotropic agents in current use for the treatment of heart failure (modiﬁed from Bistola V & Chioncel O [31]).
Adrenergic receptors agonists Calcium sensitizer PDE III inhibitor
Agents Dopamine Dobutamine Nor-epinephrine Epinephrine Levosimendan Milrinone
Mechanism of
action
D N β; HD, α β1 N β2 N α α N β1 N β2 β1 = β2 N α Calcium sensitization; HD, PDE III inhibition PDE III inhibition
Inotropic effect ↑↑ ↑↑ (↑) ↑↑ ↑ ↑
Arterial
vasodilatation
↑↑ (renal, LD) ↑ 0 ↑ ↑↑ ↑↑↑
Vasoconstriction ↑↑ (HD) ↑ (HD) ↑↑ ↑ (HD) 0 0
Pulmonary
vasodilatation
↑ or 0 ↓ or 0 (at high
PVR)
↓ or 0 (at high PVR) ↑↑ ↑↑
Elimination t½ 2 min 2.4 min 3 min 2 min 1,3 h
(active metabolite, 80 h)
2,5 h
Infusion dose b3 μg/kg/min: renal
vasodilation;
3–5 μg/kg/min:
inotropic;
N5 μg/kg/min
vasoconstrictor
1–20
μg/kg/min
0.02–10
μg/kg/min
0.05–0.5 μg/kg/min 0.05–0.2 μg/kg/min 0.375–0.75
μg/kg/min
Bolus dose No No No 1 mg during resuscitation
every 3–5 min
6–12 μg/kg over 10 min (optional, only in
euvolemic and eukalemic state)
25–75 μg/kg over
10–20 min
PDE: phospodiestarase; D: dopaminergic receptors; HD: high dose; LD: low dose; PVR: pulmonary vascular resistances; CS: cardiogenic shock.
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through its action on alpha-1 receptors and, in the case of HF, is usually
used in combination with classical inotropes in cardiogenic shock to
restore blood pressure or in association with dobutamine or inodilators
to avoid hypotension. Epinephrine causes vasodilation at low doses
(b0.01 μg/kg/min) and inotropy along with vasoconstriction at higher
doses (0.05–0.5 μg/kg/min). It is used primarily in the setting of cardiac
arrest. Epinephrine may result in lactic acidosis while its use in
cardiogenic shock has been associated with increased mortality and
should be avoided [17].
2.2. The phosphodiesterase III inhibitors
Phosphodiesterase III inhibitors include milrinone and enoximone,
although the latter is not currently available or in use inmany countries.
Phosphodiesterase III inhibitors increase intracellular cAMP levels in
cardiomyocytes by inhibiting its breakdown by the sarcoplasmic
reticulum-associated phosphodiesterase III, thus increasing intracellular
Ca2+. Besides their inotropic effect, they also cause peripheral and
pulmonary vasodilatation and thus a drop in systemic and pulmonary
pressure and resistance through an effect on vascular smooth muscle
cells. On the other hand, due to their pharmacokinetic and
pharmacodynamic characteristics, they induce tolerance [18] as well
an increase in vascular resistance in end-organs [19].
2.3. The calcium sensitizer levosimendan
Levosimendan exerts its inotropic effects through sensitization of
cardiac troponin C to Ca2+, without increasing the intracellular Ca2+
concentration, thuswithout disturbing relaxation ormyocardial oxygen
consumption/supply balance. Levosimendan also causes vasodilation by
activation of the ATP-sensitive K+ channels in vascular smooth muscle
cells, while at higher doses, it also acts as a PDEi. In addition to its
hemodynamic effects, levosimendan has further been shown to bear
pleiotropic properties beyond HF and the heart, including protection
of myocardial, renal, hepatic and neural cells from ischemia/reperfusion
injury, and further anti-inﬂammatory and anti-oxidative effects [20].
These properties seem to be primarily related to the activation of ATP-
sensitive K+ channels in mitochondria [21]. Another particular feature
of the drug is the prolonged action, compared to other inotropes, that
lasts several days after discontinuation of the infusion, which is
provided by the long elimination half-life of the active metabolite OR-
1896 of approximately 80 h. In patients with severe renal dysfunction,
the elimination half-life may be extended up to 1.5 fold, prolongingfurther the action of the drug. In a review of different meta-analyses,
levosimendan was consistently associated with lower mortality that
reached statistical signiﬁcance in most of the studies [22].
2.4. Comparing the properties of inotropes
It has been shown that all of the above inotropic agents, besides
increasing cardiac contractility, also bear vasoactive properties, causing
either vasoconstriction, as in the case of norepinephrine, epinephrine
and high-dose dopamine or vasodilation, as in the case of PDEi,
levosimendan and low-dose dobutamine. These properties should be
taken under consideration when choosing among the different
inotropes. Due to their combined inotropic and vasodilating effects,
PDEi and levosimendan are often referred to as inodilators.
Inotropes bear a non-negligible risk of important adverse events.
Dopamine may induce tachyarrhythmias, particularly at high doses
[16]. Dobutamine, apart from tachyarrhythmias, also causes
hypotension at low doses due to vasodilation. Norepinephrine may
indirectly induce arrhythmias by unbalancing myocardial oxygen
supply-demand and increasing systemic vascular resistance.
Epinephrine has several adverse effects including tachyarrhythmias,
myocardial ischemia and systemic or pulmonary hypertension.
Milrinone causes tachyarrhythmias and profound arterial hypotension,
while it should be used with caution in patients with impaired or
deteriorating renal function. Levosimendan may cause arrhythmias
and hypotension. Themost commonly encountered form of arrhythmia
is atrial ﬁbrillation, while the arrhythmogenic effect of the drug is less
pronounced compared to other inotropes due to the avoidance of
cardiomyocyte calcium overload [20,23]. Furthermore, limited data
shows that the hypotensive effect of levosimendan may not require an
excessive increase in vasopressors in cardiogenic shock [24] as in the
case of PDEi [25]. Both adverse events may be avoided or restricted if
no loading dose is administered [20].
3. Inotropes in acute heart failure
Acute HF is deﬁned as the new onset of or change in symptoms and
signs of HF that requires medical intervention and usually leads to
hospitalization [14]. Acute HF encompasses a wide spectrum of clinical
conditions, ranging from mild and gradually developing central and
peripheral congestion in the presence of chronic HF, to abrupt
congestion with acute pulmonary edema caused by an acute
hemodynamic derangement, such as a hypertensive peak, to low output
syndromes and to cardiogenic shock [26]. Prognosis varies accordingly,
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of the spectrum, respectively [27,28].
No pharmacologic therapies, including either classical drugs or novel
and investigational agents, have hitherto been shown to improve
outcomes in AHF in terms of hard endpoints (Supplementary Table 1).
As a result, recommendations for the management of AHF include
etiological treatment, when a speciﬁc treatable cause or precipitant is
identiﬁed, such as acute coronary syndromes, along with the alleviation
of symptoms caused by congestion and the restoration of cardiac output
in the case of low output states.
In AHF, inotropes are required for the treatment of the subset of
patients with low cardiac output, resulting in persistent symptomatic
hypotension and/or end-organ hypoperfusion, despite adequate
intravascular volume. In the ESC-Heart Failure Long-Term Registry,
inotropes were used in 12% of patients admitted with AHF [8].
Epidemiological evidence shows that patients with low cardiac output
and peripheral hypoperfusion comprise b10% of the AHF population,
but this particular subpopulation bears the worst prognosis with the
highest mortality rates [29]. In these patients, current guidelines
recommend the use of any of the aforementioned inotropic agents
with a class IIb recommendation [14]. It should be stressed that the
use of inotropes should be limited to the lowest dose and the shortest
possible period of time.
Identifying the patients with true end-organ hypoperfusion can be
challenging. Symptoms, signs and laboratory ﬁndings that can be used
as criteria to decide the presence of peripheral hypoperfusion include
persistent hypotension, cold and wet extremities, mottled skin, altered
mental status, oliguria, low cardiac index, elevated serum lactate,
elevated serum transaminases or low venous oxygen saturation [14].
These criteria should be used in combination and it is important to
remember that peripheral hypoperfusion may occur even in the
absence of signiﬁcant hypotension, due to sympathetic activation
causing a profound peripheral vasoconstriction [30]. At the same time,
hypovolaemia should always be excluded based on signs and tests of
adequate intravascular volume, such as presence of normal or elevated
central venous pressure, lack of inferior vena cava distensibility,
negative ﬂuid challenge or negative passive leg raising test.
Treatable causes of AHF, such as acute coronary syndrome,
pulmonary embolism, mechanical complications of myocardial
infarction, tachyarrhythmias or valvular disorders should be timely
diagnosed and managed accordingly [14]. In the latter case, inotropes
may still be needed in combination with or as a bridge to the treatment
of the relevant etiology. Furthermore, viable alternatives to inotropes,
such as mechanical circulatory support with temporary ventricular
assist devices or extracorporeal membrane oxygenation (ECMO),
should also be explored, particularly in patients not adequately
responding to inotropes.
Once inotropes are deemed necessary, the choice of the proper agent
should be based on patient’s proﬁle as determined by medical history,
background medications, hemodynamic status and comorbid
conditions [31]. In patients with decompensated ischemic HF without
true hypoperfusion, milrinone showed a deleterious effect [32], while
levosimendan has been associated with a trend towards survival
improvement in different meta-analyses [22]. Thus, it has been
proposed that levosimendan or dobutamine are more preferable
options, despite the absence of direct head-to-head comparisons [33].
In patients with right ventricular failure and/or pulmonary
hypertension, milrinone and levosimendan are preferred due to their
vasodilatory effects on pulmonary vasculature. In terms of background
medication, patients on beta blockers theoretically respond better to
levosimendan or milrinone, as these drugs act independently of the β-
adrenergic receptors; the same is true in the case of beta-1 receptor
down-regulation that has been noticed in HF [34]. Concerning the
hemodynamic status, in the presence of persistent hypotension, besides
adequate volume status, norepinephrine is the vasopressor of choice
and can be used in combination with vasodilating inotropes such asdobutamine and levosimendan in an effort to enhance cardiac
contractility while maintaining adequate blood pressure for tissue
perfusion; vasopressor may subsequently be withdrawn with the
amelioration of cardiac performance [35]. The combination of two
different classes of inotropes, in contrast, does not seem to provide
additional beneﬁt. With respect to comorbidities, in patients with
primary renal failure, one should consider the long half-lives of
milrinone and levosimendan (Table 1). In patients with cardiorenal
syndrome in the context of AHF, levosimendan may be the proper
option. In a small study in AHF, levosimendan improved glomerular
ﬁltration rate along with increasing renal blood ﬂow and renal artery
diameter [36], while the drug has further been shown to bear reno-
protective effects in experimental and clinical studies [21,37]. Finally,
in AHF-associated cardio-hepatic dysfunction, levosimendan seems to
be superior to dobutamine [38].
3.1. Inotropes in cardiogenic shock
Cardiogenic shock (CS) is a particular form of AHF with ominous
prognosis and increased mortality [39]. It is deﬁned as the presence of
SBP b90 mmHg for N30 min (or need of catecholamines to maintain
SBP N90mmHg), associatedwith clinical signs of pulmonary congestion
as well as impaired organ perfusion with at least one of the following:
(i) altered mental status, (ii) cold and clammy skin and extremities,
(iii) serum lactate N2.0 mmol/L, (iv) oliguria with urine output b30
mL/h (b0.5 ml/kg/min), caused by a cardiac condition [40]. It is
associated with signiﬁcant derangement of tissue perfusion, resulting
in a vicious circle of progressive interrelated multi-organ dysfunction
that is lethal unless proper and timely interventions are applied.
The management of CS consists of treating the etiology - as in the
case of acute coronary syndromes that represents a major cause of CS
- along with the hemodynamic support with inotropes and
vasopressors to increase cardiac output and blood pressure in order to
restore tissue perfusion. Mechanical circulatory support, with
temporary ventricular assist devices or ECMO, may be needed when
the patient is not responding to initial therapy or as a bridge to
etiological treatment, durable mechanical circulatory support or heart
transplantation. In CS, norepinephrine provides a survival advantage
over dopamine, according to a sub-analysis of the SOAP-II trial [16],
and over epinephrine, according to the OPTIMA-CC trial, in which
epinephrine induced excessive refractory HF [17]. The association of
epinephrine with increased short and medium-term mortality
compared to other inotropes and vasopressors may be related to the
greater neurohormonal activation and myocardial and renal injury
[41]. As an example for the differential effects of inotropes, it has been
shown that patients in cardiogenic shock after cardiac surgery requiring
temporary extracorporeal life support and inotrope support for
weaning may beneﬁt from levosimendan, without an increase in
norepinephrine requirements, when compared to milrinone [42].
Furthermore, a Cochrane systematic review, showed that levosimendan
may be superior to dobutamine in terms of short-term survival;
however, this ﬁnding did not translate into a signiﬁcant long-term
survival beneﬁt, while some studies included in the analysis were
considered as low-quality evidence [43].
A propensity score-matched analysis by the GREAT network showed
that combining vasopressors (epinephrine, norepinephrine, or
dopamine) with vasodilating inotropes (dobutamine, levosimendan or
PDE inhibitors) leads to better survival than vasopressors alone [35].
4. Inotropes in advanced heart failure
Patients with AdvHF represent 1–10% of all HF patients, a prevalence
that is expected to increase because of the growing HF population and
its improving survival [2]. In 2018, the Heart Failure Association of the
European Society of Cardiology updated its deﬁnition of AdvHF [2];
this new deﬁnition is provided in Supplementary Table 2.
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often unresponsive to drug therapy, poor performance status with
marked limitation in exercise capacity, signiﬁcantly impaired quality
of life (QoL), progressive deterioration of multiple organ function such
as renal and hepatic functions, intolerance to disease-modifying
therapies and repeated hospitalizations [30]. A proposed classiﬁcation
of AdvHF that identiﬁes the involvement of other organs besides the
heart allows to distinguish AdvHF from end-stage cardiac patients [44].
Due to the fact that AdvHF is a persistent condition, that usually
worsens over time, and may demand permanent solutions including
durable mechanical circulatory support and cardiac transplantation,
inotropes may be required repeatedly. Neutral results on overall long-
term survival are shown when pooling the data of all studies on
intermittent inotrope administration in AdvHF, irrespectively of the
drug [45,46]. In this setting, levosimendan may have an advantage
over the other inotropes due to the long-lasting effect of its active
metabolite OR-1896 [47]. Indeed, a number of clinical trials have
provided encouraging evidence on the use of repetitive levosimendan
infusions in AdvHF, showing improvement in functional status, QoL,
hemodynamic outcomes, and neurohormonal and inﬂammatory
markers [48–51]. A meta-analysis of 7 randomized trials including 438
patients followed for 8 months in average showed that levosimendan
led to a signiﬁcant reduction in mortality and 3-month hospitalizations
by 46% and 60%, respectively, compared to dobutamine or placebo [52].
However, themulticenter randomized trial LevoRep (n= 120) showed
no effect on the primary endpoint of improvement in functional
capacity (6-min walked distance, 6MWD, increase by 20% or more)
and QoL (Kansas City Cardiomyopathy Questionnaire, KCCQ,
improvement by 15% or more), despite a reduction in the composite
of death, heart transplantation, and acute heart failure rates [53]. In
contrast, the LION-HEART study (n= 69) met its primary endpoint of
NT-proBNP reduction, and it further showed a signiﬁcant decline in
the rate of all-cause death or HF hospitalization [54]. A meta-analysis
of all available clinical trials, conﬁrmed the effect of levosimendan on
re-hospitalization in AdvHF [55]. The ongoing LeoDOR trial tests the
hypothesis that repetitive levodimendan infusions will improve
outcomes in AdvHF patients when applied during the vulnerable post-
discharge period, when a signiﬁcant proportion of readmissions occur
[56].
Patients with AdvHF are inherently unstable and begin to
decompensate well before being hospitalized [2,57]. As illustrated in
Fig. 2, there is often a crucial interval during which the timely
recognition of signs and symptoms of decompensation can avoid
unplanned hospitalization due to haemodynamic derangement, which
seems to be followed by loss of myocardial tissue. Preventing re-Fig. 2. The variable course of decompensation in advanced heart failure. It could be
possible in many instances to identify intervals (T) during which the timely recognition
of the signs and symptoms of decompensation permit interventions that can avert
unplanned hospitalizations due to hemodynamic deterioration (modiﬁed from Oliva
et al. [65]).hospitalization in this window of opportunity represents therefore
and important target in this population. The effect of this preemptive
strategy based on repeated inodilators, such as levosimendan, remains
to be proven [56,58].
5. Inotropes and patient reported outcomes
Randomized trials have generally failed to provide compelling
evidence that inotropes improve survival endpoints in patients with
HF. Still, inotropes are indispensable in the setting of both AHF and
AdvHF as they do improve patients’ symptoms. In addition, treatment
of AdvHF patients is often primarily palliative, and HF patients seem to
attach more weight to QoL rather than to longevity [59]. Therefore,
evaluation of the effects of inotropes on patient reported outcomes
(PRO) is important. Incorporating the patient perspective through the
evaluation of PRO is becoming increasingly essential in clinical trials.
However, large randomized trials have not sufﬁciently addressed the
effects of inotropes on PRO.
A key PRO that has been broadly studied inHF is QoL through the use
of a series of well-structured and usually self-administered
questionnaires and tools [60]. A number of factors affect QoL in patients
with AHF or AdvHF, besides symptoms of central and peripheral
congestion, including neurohormonal and inﬂammatory activation,
impaired peripheral muscle perfusion and function, comorbid
conditions such as anemia or pulmonary disease, wasting and cachexia,
deconditioning, psychological impairment and depression as well as
social status [61,62]. In turn, QoL seems to be an independent predictor
of prognosis in chronic HF and impaired QoL has been associated with
reduced survival and increased event rate [63]. In the placebo arm of
the SHIFT-HF trial, impaired QoL, as determined by the lower KCCQ
tertile, was signiﬁcantly associated with increased incidence of the
primary composite endpoint of cardiovascular death and heart failure
hospitalization [63]. However, the prognostic value of QoL
questionnaires in AHF is limited.
Studies in refractory AdvHF patients have shown that treatment
with intermittent low-dose dobutamine infusions, either in outpatient
clinic or at home, improves QoL, without having an effect on survival
[45]. Similarly, small studies have shown that repeated levosimendan
administration also improves functional capacity and QoL in AdvHF
[64,65]. However, as previously stated, the two randomized trials on
repeated levosimendan infusions, LevoRep and LION-HEART, provided
conﬂicting evidence.
6. Conclusions
Inotropes increase cardiac output by enhancing cardiac contractility
through different mechanisms of action, but they also bear variable
vasodilatory or vasoconstrictive effects depending on agent and dosage.
They constitute an important tool for the treatment of patientswith AHF
or AdvHF, as they are often effective in improving hemodynamics and
symptoms. However, their administration has been associated with
increased short and long-termmortality due to frequent adverse effects,
but also due to their improper use. The classes of inotropes currently
used in HF are the β-adrenergic receptor agonists including dopamine,
dobutamine and the catecholamines norepinephrine and epinephrine,
the PDE III inhibitormilrinone and the calcium sensitizer levosimendan.
In AHF, inotropes are indicated with a IIb recommendation by the
ESC guidelines only for patients with peripheral hypoperfusion because
of low cardiac output. Identifying patients with truly low cardiac output
in need of inotropic support can be challenging, while selecting the
proper agent according to patients’ clinical proﬁle and limiting infusion
to the shortest time and lowest dose possible are important to optimize
inotrope use. Levosimendan bears some pharmacological and
pharmacokinetical advantages in this setting, but its positive clinical
evidence is based mainly on observational studies, small randomized
Fig. 3. Practical recommendations for the use of inotropes in acute heart failure. SBP, systolic blood pressure; CVP, central venous pressure; ICV, inferior vena cava; PCI, percutaneous
coronary intervention; ACS, acute coronary syndrome; HR, heart rate; RR, respiratory rate; PCWP, pulmonary capillary wedge pressure; CABG, coronary artery bypass surgery; IMV,
intermittent mechanical ventilation; SVV, stroke volume variation; PPV, pulse pressure variation; CI, cardiac index.
88 D. Farmakis et al. / International Journal of Cardiology 297 (2019) 83–90regulatory trials and meta-analyses as the large randomized trials have
hitherto provided neutral results.
In AdvHF, inotropic agents are required for the relief of persistent
symptoms and the improvement of quality of life. Day clinic-based or
home-based repetitive infusions may reduce hospital admission,
which is a key factor in the quality of live and perhaps overall prognosis
of the disease. Levosimendan bears an advantage in this setting due to
its long-acting active metabolite, but evidence from properly powered
randomized trials are awaited.
Fig. 3 provides a practical approach to the three main steps required
for the optimal use of inotropes in HF, namely (i) the identiﬁcation of
the right patient, (ii) the choice of the proper inotrope and (iii) the
deﬁnition of the adequate weaning time.
The effects of inotropes on PRO and QoL in general, remain poorly
deﬁned, and more studies on this important and clinically meaningful
aspect of AHF and AdvHF patient care are warranted.Sources of funding
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